Taylor St Cap (@TaylorStCap) header
Taylor St Cap (@TaylorStCap) profile picture

Stocks and other musings

Joined October 2025
Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)
What a day. Had excellent protection from $MLTX and decent protection from $PODD, and even $CBRS held in I suppose. What a week. Time to touch grass and deploy into equities. Generated significant alpha today and feel good. Market is way off on $PODD / $TNDM debate.
226
Market not understanding just how consequential this is. $CBRS
This quoted post is unavailable.
3
768
$PODD down again on Truist downgrade. I always wonder who sells on SS downgrades. The stock is down 60% … this stuff is all already understood. Did anyone really need Truist to tell them that more competition wa coming to this space?
2
284
Here’s why markets are so F’ing hard: $PODD is sort of an obvious short. Massive growth decel. Continuous quarters of guidance cuts. CEO that frankly appears clueless like a deer in the headlights. Incoming competitors in tubeless insulin that challenge their tech superiority
1
246
and again the lack of regard for manufacturing know-how. Say what you will about $PODD, but they have a ton of scar tissue and have a dramatic edge here over $TNDM and other newcomers. This gets lost on some. 18x NTM GAAP is probably a fair multiple here and am happy to ride
1
78
20%+ earnings growth here to a nice mid-to-high teens IRR. Long $PODD.
66
Fair to say I’ve lost my edge notably this year. Every dip I’ve analyzed and passed on I should have bought. Every dip I’ve bought has kept dipping. Down week after week after week. Maybe @FDA denies best-in-disease $MLTX and maybe diabetes leader $PODD gets beat by newcomers
1
1
432
like $TNDM and $SENS (each of whom have 0 manufacturing know-how) and maybe $SGI never sells another mattress and maybe $CBRS is fraudulent and @CulperResearch knows more about wafer scale chip design than $AMD and $MSFT and maybe $NNBR never sells another liquid cooling system
1
352
ever again as new data center builds go to 0 … maybe. That’s how my book is priced. So there should be upside if any of that doesn’t happen. But I’ve gone from hopeful to very frustrated recently which tells me it might be time to touch grass and call it a year.
83
$MLTX: adds from Deep Track and Duquesne (Druck) ahead of catalyst rich 4Q’26 - 1H’27 $PODD: massive ($700m) buy from Sessa, who I think very highly of I’ve recently sized into both, with $MLTX as a spec biotech play and $PODD as a dislocation play that’s sold off far too much
1
353
Curious, Adam. Thoughts on your thesis after the very disappointing $ZURA data? it appears sonelokimab may have the edge after all here and is likely to be given priority review by FDA. An update to your thesis would be appreciated
Replying to @A_May_MD
Slide 5: Debunking the myth of IL17*F* Part 4 The next examples of *clinical* data that debunk the importance of hitting IL17F are the $MLTX Sonelokimab sagas. Sonelokimab was the much-hyped IL17 inhibitor developed by Moonlake Therapeutics. It was supposed to be a fast-follower to Bimzelx with “me-better” potential. Why? Sonelokimab had ~6x higher IL17FF affinity than Bimzelx! The logic here was simple: If hitting IL17F is what set Bimelx apart as the best IL17 inhibitor, then a drug that hits IL17F *even harder* would be even BETTER! Right?! Well, not only did Sonelokimab yield lower efficacy in psoriasis than Bimzelx, it even yielded lower efficacy than Taltz that doesn’t hit IL17F at all! And that isn’t even adjusting Taltz to the higher dose used in IXORA-P… Then, in HS sonelokimab actually *missed* in one of its two phase 3 trials! Now, some of this was just bad luck for sonelokimab. It is *definitely* active because it does hit IL17A quite well. However, its IL17F affinity being GREATER than its IL17A affinity may have ultimately been a *disadvantage* instead of the advantage the market thought it would be. I wonder if highly abundant IL17F actually acted as a drug sink for sonelokimab and hindered its ability to cause maximal suppression of 17A. In any case, the $MLTX/Sonelokimab case study showed us this: Maximizing IL17F affinity did NOT yield a better IL17 inhibitor…if anything, it gave us a *worse* one. This is yet another piece of clinical evidence pointing us *away* from hitting 17F and *toward* 17A, like $ZURA is going to do with Tibulizumab.
1
1
523
I’d recommend reading some of these patient reviews of $MLTX sonelokimab … given the data (either best in class or extremely competitive with Bimekizumab) and stellar patient reviews, it’s hard to imagine the @FDA would keep this life changing medication from patients. Powerful
1
4
475
statements like “miracle for me”, “I can’t wait for this to hit the market”, “two words - life changing”, “absolutely incredible results”, “24 hours after my injection I noticed both flares have gone down significantly”, “it actually looks promising” $MLTX
1
2
306
“it was like magic for me”, “I finally feel some relief”, “I saw much more improvement very quickly after that started” $MLTX … hard to imagine denying patients this medication … excited for a priority review decision this or next week.
2
320
I would imagine this is a contra indicator since the only other biotech I have ever bought is $AMLX … but can someone explain to me why $MLTX isn’t a $60 stock? 97% of patients with moderate+ HS don’t receive advanced therapy. They have the best molecule. Commercial launch
1
4
495
imminent with very defined upcoming catalysts including BLA acceptance in HS within the next 2 wks, phase 3 initiation of sonelokimab in PPP within 3 wks, phase 2 POLARIS in early ‘27, topline phase 3 IZAR-2 in early ‘27 … just absolutely loaded for $500m EV. No brainer $MLTX
1
181
I stand with Jensen here. His company. His vision. Shareholders love him. Employees love him. Board has no right to remove the man at the destruction of shareholder value. Put it to a vote. Typical corporate rule book does not apply here. #IStandWithJensen
4
299
✅ bottom appears to be in here. $SGI green on a bad print as the market better appreciates that they continue to take share. Falling 10yr helpful
This quoted post is unavailable.
1
371